GNMSF
Genmab A/S
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong buy
+79/100
Last price
376.00
▼ 20.97 (5.28%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
396.97
Day high
384.00
Day low
376.00
Volume
202
Market cap
$23.12B
P/E (TTM)
29.70
52W range
232.34 – 396.97
Trailing performance
Returnvs SPY
1W
+5.92%
+4.2%
1M
+14.20%
+12.9%
3M
+30.21%
+27.0%
6M
+43.90%
+29.1%
YTD
+19.75%
+6.0%
1Y
+13.94%
-1.6%
3Y
+5.53%
-76.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GNMSF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
668.06K
Total on file
Fundamentals
Market cap$23.12B
Enterprise value$26.21B
Revenue (TTM)$4.13B
Gross profit$3.84B
EBITDA$1.38B
Net income$788.00M
EPS (TTM)$12.66
Free cash flow$870.63M
Total cash$1.51B
Total debt$5.27B
Book value / share$99.78
Shares outstanding61.49M
Float55.78M
Short % of float—
Dividend yield0.00%
Beta (5Y)0.65
Valuation & profitability ratios
Trailing P/E29.70
Forward P/E27.21
PEG ratio4.75
Price / sales—
Price / book3.77
EV / revenue6.35
EV / EBITDA19.04
Gross margin93.03%
Operating margin35.24%
Profit margin19.07%
Return on equity14.00%
Return on assets8.79%
Debt / equity88.52
Current ratio2.46
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.72B | $3.12B | $2.39B | $2.09B | — | +19.2% |
| Operating revenue | $3.67B | $2.98B | $2.27B | $1.97B | — | +23.2% |
| Cost of revenue | $238.00M | $143.00M | $33.00M | $0 | — | +66.4% |
| Gross profit | $3.48B | $2.98B | $2.36B | $2.09B | — | +16.9% |
| Research & development | $1.61B | $1.41B | $1.11B | $800.53M | — | +13.6% |
| Selling, general & admin | $626.00M | $549.00M | $478.00M | $385.15M | — | +14.0% |
| Total operating expense | $2.23B | $1.96B | $1.58B | $1.19B | — | +13.7% |
| Operating income | $1.25B | $1.01B | $772.00M | $902.00M | — | +23.2% |
| Net interest income | $77.00M | $126.00M | $132.00M | $41.02M | — | -38.9% |
| Pre-tax income | $1.20B | $1.33B | $817.00M | $999.58M | — | -9.2% |
| Tax provision | $241.00M | $193.00M | $186.00M | $214.89M | — | +24.9% |
| Net income | — | $1.13B | $631.00M | $784.70M | $450.16M | — |
| Net income to common | $963.00M | $1.13B | $631.00M | $784.70M | — | -15.0% |
| Basic EPS | 15.50 | 17.05 | 9.67 | 12.15 | — | -9.1% |
| Diluted EPS | 15.37 | 16.93 | 9.58 | 12.04 | — | -9.2% |
| EBIT | $1.26B | $1.34B | $827.00M | $1.01B | — | -5.9% |
| EBITDA | $1.34B | $1.40B | $870.00M | $1.06B | — | -4.8% |
| Basic shares | 62.15M | 64.19M | 65.31M | 65.78M | — | -3.2% |
| Diluted shares | 62.69M | 64.63M | 65.90M | 66.01M | — | -3.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.72B | $1.38B | $2.20B | $1.42B | +24.3% |
| Cash & short-term investments | $1.72B | $2.95B | $4.17B | $3.21B | -41.9% |
| Accounts receivable | $1.11B | $923.00M | $733.00M | $822.12M | +20.5% |
| Inventory | $18.00M | $9.00M | $8.00M | $0 | +100.0% |
| Total current assets | $2.88B | $3.90B | $4.91B | $4.06B | -26.0% |
| Property, plant & equipment | $280.00M | $265.00M | $244.00M | $190.27M | +5.7% |
| Goodwill & intangibles | $9.48B | $2.08B | $15.00M | $21.01M | +355.0% |
| Total assets | $12.87B | $6.41B | $5.23B | $4.33B | +100.7% |
| Total current liabilities | $1.43B | $744.00M | $368.00M | $262.38M | +91.8% |
| Current debt | $273.00M | — | — | — | — |
| Long-term debt | $5.00B | — | — | — | — |
| Total debt | $5.43B | $144.00M | $114.00M | $85.93M | +3,668.1% |
| Total liabilities | $7.03B | $1.28B | $545.00M | $408.32M | +450.2% |
| Retained earnings | $4.10B | $3.39B | $2.74B | $2.13B | +20.8% |
| Shareholder equity | $5.85B | $5.14B | $4.69B | $3.93B | +13.8% |
| Working capital | $1.46B | $3.16B | $4.54B | $3.80B | -53.8% |
| Net tangible assets | -$3.63B | $3.05B | $4.67B | $3.91B | -218.9% |
| Shares issued | 64.24M | 66.19M | 66.07M | 65.96M | -2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.20B | $1.33B | $817.00M | $999.58M | -9.2% |
| Depreciation & amortisation | $71.00M | $60.00M | $43.00M | $52.10M | +18.3% |
| Stock-based compensation | $128.00M | $105.00M | $85.00M | $63.18M | +21.9% |
| Change in working capital | $225.00M | -$109.00M | $198.00M | -$264.83M | +306.4% |
| Operating cash flow | $1.19B | $1.13B | $1.07B | $563.05M | +5.3% |
| Capital expenditure | -$55.00M | -$44.00M | -$54.00M | -$45.63M | -25.0% |
| Investing cash flow | -$5.64B | -$1.45B | -$185.00M | -$397.39M | -290.0% |
| Share buybacks | -$430.00M | -$560.00M | -$81.00M | -$130.69M | +23.2% |
| Financing cash flow | $4.79B | -$566.00M | -$89.00M | -$113.56M | +946.1% |
| Free cash flow | $1.13B | $1.08B | $1.02B | $517.42M | +4.5% |
| End cash position | $1.72B | $1.38B | $2.20B | $1.42B | +24.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.16B | $896.00M | $1.06B | $1.02B | $925.00M | — | +28.9% |
| Operating revenue | $1.16B | $888.00M | $1.00B | $1.02B | $925.00M | — | +30.1% |
| Cost of revenue | $84.00M | $65.00M | $81.00M | $58.00M | $57.00M | — | +29.2% |
| Gross profit | $1.07B | $831.00M | $977.00M | $964.00M | $868.00M | — | +28.9% |
| Research & development | $459.00M | $440.00M | $526.00M | $357.00M | $364.00M | — | +4.3% |
| Selling, general & admin | $205.00M | $166.00M | $208.00M | $148.00M | $144.00M | — | +23.5% |
| Total operating expense | $664.00M | $606.00M | $734.00M | $505.00M | $508.00M | — | +9.6% |
| Operating income | $407.00M | $225.00M | $243.00M | $459.00M | $360.00M | — | +80.9% |
| Net interest income | -$74.00M | -$98.00M | $4.00M | $29.00M | $16.00M | — | +24.5% |
| Pre-tax income | $295.00M | $74.00M | $55.00M | $482.00M | $423.00M | — | +298.6% |
| Tax provision | -$8.00M | $21.00M | $24.00M | $81.00M | $87.00M | — | -138.1% |
| Net income | $303.00M | $53.00M | $31.00M | $401.00M | $336.00M | — | +471.7% |
| Net income to common | $303.00M | $53.00M | $31.00M | $401.00M | $336.00M | — | +471.7% |
| Basic EPS | 4.94 | 0.84 | — | — | 5.44 | 3.06 | +488.1% |
| Diluted EPS | 4.91 | 0.83 | — | — | 5.42 | 3.05 | +491.6% |
| EBIT | $405.00M | $186.00M | $99.00M | $485.00M | $432.00M | — | +117.7% |
| EBITDA | $431.00M | $215.00M | $120.00M | $503.00M | $448.00M | — | +100.5% |
| Basic shares | 61.34M | 63.10M | — | — | 61.76M | 63.73M | -2.8% |
| Diluted shares | 61.71M | 63.86M | — | — | 61.99M | 63.93M | -3.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.50B | $1.52B | $1.72B | $1.76B | $1.30B | -1.2% |
| Cash & short-term investments | $1.50B | $1.52B | $1.72B | $3.41B | $2.90B | -1.2% |
| Accounts receivable | $1.21B | $968.00M | $1.11B | $1.05B | $998.00M | +25.2% |
| Inventory | $18.00M | $21.00M | $18.00M | $14.00M | $13.00M | -14.3% |
| Total current assets | $2.80B | $2.57B | $2.88B | $4.47B | $3.91B | +8.9% |
| Property, plant & equipment | $254.00M | $265.00M | $280.00M | $266.00M | $277.00M | -4.2% |
| Goodwill & intangibles | $9.23B | $9.30B | $9.48B | $2.10B | $2.11B | -0.8% |
| Total assets | $12.52B | $12.38B | $12.87B | $7.02B | $6.46B | +1.1% |
| Total current liabilities | $1.14B | $1.18B | $1.43B | $741.00M | $629.00M | -3.2% |
| Current debt | $294.00M | $275.00M | $273.00M | — | — | +6.9% |
| Long-term debt | $4.84B | $4.93B | $5.00B | — | — | -1.9% |
| Total debt | $5.27B | $5.35B | $5.43B | $142.00M | $148.00M | -1.5% |
| Total liabilities | $6.56B | $6.69B | $7.03B | $1.27B | $1.16B | -2.0% |
| Retained earnings | $4.42B | $4.09B | $4.10B | $4.03B | $3.60B | +8.1% |
| Shareholder equity | $5.96B | $5.68B | $5.85B | $5.75B | $5.30B | +4.8% |
| Working capital | $1.66B | $1.40B | $1.46B | $3.73B | $3.28B | +19.1% |
| Net tangible assets | -$3.27B | -$3.62B | -$3.63B | $3.65B | $3.19B | +9.7% |
| Shares issued | 62.40M | 64.25M | 64.24M | 64.21M | 64.15M | -2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $295.00M | $74.00M | $55.00M | $482.00M | $423.00M | +298.6% |
| Depreciation & amortisation | $26.00M | $29.00M | $21.00M | $18.00M | $16.00M | -10.3% |
| Stock-based compensation | $37.00M | $49.00M | $36.00M | $34.00M | $33.00M | -24.5% |
| Change in working capital | -$267.00M | -$113.00M | $253.00M | $2.00M | -$105.00M | -136.3% |
| Operating cash flow | $51.00M | $3.00M | $301.00M | $536.00M | $62.00M | +1,600.0% |
| Capital expenditure | -$3.00M | -$5.00M | -$13.00M | -$2.00M | -$10.00M | +40.0% |
| Investing cash flow | $2.00M | -$9.00M | -$5.57B | -$54.00M | $26.00M | +122.2% |
| Share buybacks | $0 | -$96.00M | $0 | -$24.00M | -$406.00M | +100.0% |
| Financing cash flow | -$75.00M | -$177.00M | $5.23B | -$21.00M | -$406.00M | +57.6% |
| Free cash flow | $48.00M | -$2.00M | $288.00M | $534.00M | $52.00M | +2,500.0% |
| End cash position | $1.50B | $1.52B | $1.72B | $1.76B | $1.30B | -1.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $7.94B | +20.0% |
| Next quarter | — | — | $8.36B | +25.1% |
| Current year | — | — | $29.50B | +25.6% |
| Next year | — | — | $34.28B | +16.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.12%
Held by institutions47.30%
Institutions holding406
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
358.65
+4.84% from price
SMA 20
348.12
+8.01% from price
SMA 50
329.27
+14.19% from price
SMA 100
296.67
+26.74% from price
SMA 200
296.22
+26.93% from price
EMA 12
359.71
+4.53% from price
EMA 26
347.27
+8.27% from price
EMA 50
331.36
+13.47% from price
RSI (14)
67.2
Neutral
MACD (12,26,9)
12.44
Hist 2.66
ATR (14)
7.38
1.96% of price
Realised vol 30D
40.5%
Annualised
Bollinger upper
380.23
20, 2σ
Bollinger lower
316.02
20, 2σ
50 / 200 cross
Golden
329.27 vs 296.22
Trend bias
Above 200
+26.93%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.12
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
40.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.0%
Peak to trough
Max drawdown 5Y
-62.4%
Peak to trough
ATR 14
7.38
1.96% of price
Beta (reported)
0.65
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
Headlines
Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?
Simply Wall St. · 7h ago
AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%
Simply Wall St. · 9h ago
AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%
GuruFocus.com · 18h ago
European shares rise as retreating bond yields and oil prices boost risk appetite
Reuters · 21h ago
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
MT Newswires · 21h ago
Genmab’s Lymphoma Bet Delivers a 51% Knockout
Moby · 21h ago
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
BioPharma Dive · 22h ago
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
Zacks · 24h ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.